Research Reports | Market Assessment
April 2016

Age-Related Macular Degeneration | Current Treatment | US | 2016

Anti-vascular endothelial growth factor (VEGF) therapy is the standard of care for treating wet age-related macular degeneration (AMD), with several commercially available options. Use of off-label Avastin places pressure on the U.S. branded market; however, Eylea continues to gain market share. Additionally, with no currently available treatments, there is commercial opportunity for first-to-market dry AMD therapies. The Age-Related Macular Degeneration | Current Treatment overview provides a synopsis of current treatment goals, key therapies, and medical practice in the G7 markets, while the Dry and Wet Age-Related Macular Degeneration | Current Treatment | US detailed, expanded analysis offers a snapshot of how U.S. ophthalmologists prescribe currently available therapies as well as insight into the factors driving such prescribing habits.

Login to access report
Back to all Market Assessment reports
Login to access report

launch Related Market Assessment Reports